The U.S. is making it harder for the rest of the world to get COVID vaccines

Advertisement
Excerpt Jane Hu slate.com

In June, the World Health Organization, along with partners the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance, released a plan called COVAX to pool nations’ resources for developing and purchasing COVID-19 vaccines. At the time, investing in vaccine development was a risky proposition; it was a gamble whether any of the more than 100 vaccines in development would be safe, effective, and make it to market. COVAX allowed countries to pool resources and buy into a “portfolio approach”—their contribution bought into a pool of vaccine investments. “You could aggregate demand and use market power to get better prices for vaccines,” says Udayakumar. Once a vaccine was available, doses would be distributed to all participating countries at the same rate, based on their total population, according to a Gavi explainer written in September.

But as soon as promising vaccine trial results were released, rich countries directed their resources away from COVAX and toward pharmaceutical companies directly. “Rather than COVAX being the major platform purchasing vaccines, what we saw instead was that most countries in the world decided to go out and buy or reserve vaccine doses on their own bilateral deals,” says Udayakumar. Wealthier countries had the political and financial power to negotiate deals directly with Pfizer, Moderna, and AstraZeneca, often issuing emergency use orders that expedited the procurement process. Of the 8.2 billion confirmed vaccine doses purchased so far, more than 7 billion have come directly from such deals, with just 1.1 billion through COVAX. “There’s only so much capacity in the world to produce those vaccines, and that capacity was tied up by a few rich countries; there was nothing left over for the rest,” says Leena Menghaney, global intellectual property adviser for the Médecins Sans Frontières Access Campaign. To Menghaney’s point, the U.S. has individually secured more doses than COVAX. Our supply is nearly enough to vaccinate the entire U.S. population at least twice over and constitutes nearly 15 percent of the world’s total confirmed purchases.

Continue Reading at Jane Hu

Comments

VIP

Join the Conversation

VIP members get the ability to comment on articles.

Recommended

Trending on HotAir Videos